Brexanolone Production Cost Reports

This report gives the detailed analysis needed to set up a brexanolone production plant. It works through the main cost areas, from the cost of brexanolone production and the brexanolone plant cost to the wider brexanolone production plant cost. It also looks at what it takes to run the plant day to day. That covers the production process, raw materials, utilities, infrastructure, machinery & technology, manpower, packaging, transportation, and more.

Brexanolone Market Analysis: Demand and Supply Analysis, and Sourcing

Brexanolone is a neuroactive steroid, chemically identical to the endogenous neurosteroid allopregnanolone. It works as a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors, strengthening inhibitory signaling. Sage Therapeutics developed it as SAGE-547 and marketed it as Zulresso, which the FDA cleared as the first drug specific to postpartum depression. Patients received it as a 60-hour continuous IV infusion under a restricted REMS program. Sage later pulled Zulresso from the US market, and the FDA withdrew the approval soon after.

With the branded product gone, finished brexanolone has no active commercial demand. What remains is reference-standard use, since allopregnanolone is a long-studied research molecule carried under the same CAS number. Anyone modeling demand and supply now has to weigh the withdrawn status, the steroid precursor market, the oral successor zuranolone, and residual interest in the neurosteroid class. Reference-grade material moves in milligram-to-gram quantities through catalog suppliers such as MedChemExpress, Selleckchem, and Cayman Chemical. On receipt, buyers verify assay by HPLC, related steroid impurities, chiral purity, residual solvents, and endotoxin.

Summary of the Product, Grades, and Uses

The molecular formula for Brexanolone is C21H34O2, and the molar mass is about 318.5 g/mol under CAS 516-54-1, shared with allopregnanolone; the systematic name is 3α-hydroxy-5α-pregnan-20-one. Physically it is a white crystalline steroid, practically insoluble in water but soluble in ethanol, DMSO, and other organic solvents. Because it is so poorly water-soluble, Zulresso shipped as a sterile concentrate at 100 mg in 20 mL, solubilized in betadex sulfobutyl ether sodium, the cyclodextrin sold as Captisol.

Two grades reached the market. Pharmaceutical API grade met FDA specifications and shipped internally for Zulresso fill-finish, while reference-standard grade sells in milligram-to-gram quantities to research labs and CROs.

Postpartum depression was the only approved indication under the Zulresso brand. Adult patients received a single 60-hour IV infusion with the dose titrated up and back down over the course. The neurosteroid acts fast, which set it apart from oral antidepressants that take weeks, but dosing had to run in a certified healthcare setting under continuous monitoring for sedation and loss of consciousness. Reference-standard demand covers neuroscience and GABA-A pharmacology research at low tonnage, though it holds firmer per-gram pricing.

Main End-Uses of Brexanolone

While Zulresso was on the market, postpartum depression was the drug's only clinical end-use. The 60-hour infusion delivered a fast antidepressant response in adults with moderate to severe disease, dispensed through certified infusion centers, hospital pharmacies, and specialty pharmacies working under the REMS. Uptake stayed low because the infusion format, the monitoring load, and the high course price together limited real-world use. Before administration, hospital pharmacies checked assay, related steroid impurities, and container integrity.

Neuroscience and pharmacology research is the outlet that survived the withdrawal. Reference-grade allopregnanolone supports GABA-A receptor studies, neurosteroid signaling work, and comparison against newer agents, bought mainly by academic labs and CROs at milligram-to-gram scale. Suppliers release the material with full analytical documentation for publication and regulatory use, and buyers check chiral purity, related pregnane impurities, and structural identity by NMR and MS.

A third slice of demand belongs to the neurosteroid class rather than to brexanolone itself. Sage and Biogen moved the class toward the oral successor zuranolone, sold as Zurzuvae, a separate synthetic neurosteroid taken as a short oral course rather than an infusion. Reference suppliers keep brexanolone in the catalog as the parent comparator for that research. Quantities are very small, but the material commands firm pricing for high-purity lots.

Brexanolone Market Risks

The dominant risk is that the product itself has been withdrawn. No branded commercial route runs today, and any re-entry would need a fresh application and a fresh business case. The infusion format was the original commercial problem, since a 60-hour hospital stay is costly, hard to schedule, and ties up a monitored bed, and the REMS added monitoring and certification costs that a simple injectable does not carry. The oral successor zuranolone has since pulled interest toward tablets rather than infusions. Steroid precursor supply is niche, so the feedstock stays thin and specialty-priced. Whatever research demand remains is low in volume, spread across academic labs, CROs, and reference suppliers, and cannot support a dedicated plant.

Manufacturing has its own risks. The route depends on stereoselective reduction of a 5α-pregnane precursor to set the 3α-hydroxy configuration, and any drift in stereochemistry produces the wrong diastereomer and lowers assay. Purification is crystallization-heavy, so yield is lost at the reduction, the workup, and each crystallization in turn. The Captisol formulation step is a control point of its own, because the cyclodextrin complex governs solubility and stability. Aseptic fill of a low-concentration steroid solution leaves little room for particulate or potency drift. Most rejected batches trace back to diastereomer content and related-substance failures.

Brexanolone Production Process and Main Cost Drivers

This section traces the full value chain, from steroid precursor receipt through stereoselective reduction, crystallization, purification, drying, Captisol formulation, and aseptic fill-finish.

1. By Stereoselective Reduction of a 5α-Pregnane Precursor to the 3α-Hydroxy Steroid: The main inputs are 5α-dihydroprogesterone or a related pregnane, a reducing system such as a ketoreductase or a metal hydride, cyclodextrin for encapsulation, crystallization solvents & pH-control acids, betadex sulfobutyl ether sodium & water for injection.

Production opens with receipt and QC of the 5α-pregnane precursor and the reducing system. The precursor is reduced at the 20-keto or 3-keto position to set the 3α-hydroxy-5α configuration that defines allopregnanolone. A ketoreductase route gives high diastereoselectivity, often above 99 to 1 for the 3R form, and runs with cyclodextrin encapsulation of the substrate; a chemical hydride route is the alternative and needs a tighter workup to control the diastereomer. Crude brexanolone is extracted and taken into a first crystallization from a mixed solvent, and a second crystallization removes the unwanted diastereomer and related steroids.

The dried API is milled, tested against the drug-substance monograph, and released. For finished product, brexanolone is complexed with betadex sulfobutyl ether sodium and aseptically filled into vials. The main levers on cost are precursor price, reduction selectivity, crystallization recovery, and cyclodextrin load.

Main Factors Affecting Brexanolone Production Cost

The 5α-pregnane precursor dominates the raw material line, a specialty steroid intermediate with a narrow supplier base and specialty pricing. Reducing-system choice is the next largest cost, because an engineered ketoreductase carries enzyme and licensing charges that a hydride route does not. Betadex sulfobutyl ether sodium is a real cost in the finished product, since the Captisol complex needs a high cyclodextrin-to-drug ratio. Crystallization solvents and their recovery form a steady variable line, and steam, chilled water, and electricity for reaction, crystallization, and drying are ordinary utility items. Testing is a further recurring expense through chiral HPLC, related-substance HPLC, and endotoxin work, with GMP documentation and regulatory upkeep carried as fixed overhead that is heavy relative to the tiny API tonnage.

Unit cost also moves with the specialty steroid market: any tightness in the pregnane precursor lengthens lead time and raises price. Shifting to finished sterile product adds Captisol use, aseptic handling, and testing overhead. At the very small batch sizes typical for a neurosteroid, reactor and crystallizer on-stream time weighs heavily, so a brexanolone line only makes sense as a small campaign inside a broader steroid or sterile facility. Qualifying that supply for any drug filing takes months of audit and stability work, and because the cleanroom, reactor, and aseptic-fill line carry heavy fixed overhead across a narrow volume, utilization ultimately decides the unit cost.

Raw Materials for Brexanolone Production Plant and its Procurement

The 5α-pregnane precursor is the primary feedstock, drawn from specialty steroid houses that run pregnane and progesterone chemistry, mainly in China, India, and Europe. Its price reflects the multi-step steroid synthesis behind it and the low volume base. The reducing system arrives either as an engineered ketoreductase from an enzyme supplier or as a metal hydride from bulk fine chemical suppliers. Betadex sulfobutyl ether sodium, the Captisol excipient, comes from Ligand and its licensed makers under CAS 182410-00-0. Crystallization solvents, cyclodextrin for encapsulation, and process acids are supplied by fine chemical vendors, and water for injection is made on site for the finished sterile product.

The cheapest precursor is not always the cheapest route to finished API. A pregnane lot with elevated related steroids raises crystallization duty and off-grade output, so the initial saving is lost in rework. Reducing-system quality feeds straight into diastereoselectivity, which sets how much polishing each batch needs, and Captisol quality matters for the finished product because the complex governs solubility and shelf life. Taken together, precursor assay, related steroids, reduction selectivity, and cyclodextrin grade account for most of the variable cost per gram.

Contracts specify precursor purity, related-steroid limits, water content, and residual metals, and every incoming lot is quarantined until QC release. Vendor qualification for a GMP steroid plant runs through on-site audits, impurity-profile review, and lot-to-lot monitoring, and long-term agreements with two qualified precursor suppliers help steady both cost and timing. Siting the plant inside a steroid or sterile-injectable cluster in China, India, or Europe adds a genuine freight and compliance advantage.

Sustainability and Regulatory Requirements

Environmental and occupational concerns center on steroid handling, solvent-heavy crystallization, and reducing-agent waste. Standard controls rely on closed handling of the potent steroid, solvent recovery loops, and incineration of process residues. Wastewater carries trace steroid, spent solvent, and salt streams that need chemical treatment before discharge. Because the API is pharmacologically active at low doses, dust control and containment matter throughout. Switching from the chemical route to enzymatic reduction cuts metal-hydride waste, solvent load, and heavy-metal residues.

Regulatory scope follows from the API's former use in an approved injectable. In the US, brexanolone drug substance fell under FDA cGMP oversight per 21 CFR 210/211, and Zulresso carried a REMS for the infusion; the FDA later withdrew the Zulresso approval at the sponsor's request. ICH Q3A, Q3C, and Q3D govern impurities, residual solvents, and elemental impurities for any steroid API, and aseptic manufacture of the finished product ran under sterile-injectable GMP. Sites typically carry ISO 14001 and ISO 45001 certification. No USP monograph for the finished drug is maintained now that the product is off the market.

CAPEX and OPEX for a Brexanolone Production Plant

The process needs both a steroid synthesis train and a sterile fill line. It starts with steroid-precursor cold storage, a jacketed reduction reactor, and a workup and extraction train, followed by crystallization vessels, a centrifuge or filter for solids, and a vacuum dryer for the API. For finished product, a Captisol formulation vessel, sterile filtration, and an aseptic vial-fill line under Grade A air complete the sequence. Utilities cover clean steam, purified water, water for injection, chilled brine, nitrogen, and a thermal oxidizer for solvent vents. A laboratory block typically houses chiral HPLC, related-substance HPLC, LC-MS, and endotoxin testing, while civil works provide contained steroid process bays, aseptic corridors, gowning, and a controlled-access API warehouse.

Operating cost is set by the same materials and control points that shape the process. The variable side is dominated by the pregnane precursor, the reducing system, and Captisol, alongside solvents, water for injection, labor, GMP documentation, testing, wastewater treatment, and packaging. Cost per gram then turns on reduction selectivity, crystallization recovery, and aseptic-fill yield. Plant-to-plant differences come down to capacity, the choice between the enzymatic and chemical routes, sterile-fill scope, and containment class. Precursor price, reduction selectivity, Captisol load, and GMP overhead then determine the running cost.

Plant Location and Investment Factors

A workable site sits within a steroid or sterile-injectable cluster that supplies pregnane feedstock, the cyclodextrin excipient, and aseptic-fill services. A trained cGMP steroid and sterile workforce is close to essential given the containment profile. Chinese steroid clusters in Hunan and Zhejiang carry both precursor and downstream capacity, Indian clusters in Hyderabad and Telangana suit a steroid-API entrant, and European sterile-fill hubs in Italy, Germany, and Ireland cover the finished-product side. On the utility side, the site also needs water-for-injection capacity and contained steroid handling.

Given the Zulresso withdrawal, the first question is whether a dedicated plant is worth building at all. An API-only line for reference and research supply is too small to carry a stand-alone plant, so a campaign slot inside a broader steroid or sterile facility is the only sensible model today. Any case for re-entry would depend on a home-infusion or lower-cost delivery model that the original launch never reached. Scale has to match a research-only market unless a new indication appears, and the main lever left on cost is the choice between the enzymatic and chemical reduction routes, together with campaign length and containment class.

Major Brexanolone Producing Regions

During the Zulresso years, the US was the sole commercial production region for brexanolone, through Sage Therapeutics and its contract partners, but that base closed once Sage pulled the product and the approval lapsed. Reference-grade material is now finished by catalog suppliers in the US, Europe, and China. Steroid precursor chemistry sits mainly in China and India, which host most pregnane and progesterone capacity, so any future API work would most likely start in a Chinese or Indian steroid cluster. Betadex sulfobutyl ether sodium for the formulation comes from Ligand and its licensed makers. Research-grade lots are finished on small lines at the catalog houses.

Key Brexanolone Producers

Sage Therapeutics, Inc. (former marketer)

• Developed brexanolone as SAGE-547 and brought Zulresso to market as the first drug for postpartum depression.
• Ran commercial supply through contract API and aseptic fill-finish partners under a restricted REMS program.
• Later pulled Zulresso from the US market and requested withdrawal of the approval, which the FDA granted.
• Regulatory record covers the original FDA approval, the Zulresso REMS & the later approval withdrawal.

MedChemExpress LLC

• Sells reference-standard allopregnanolone, listed under the brexanolone and SAGE-547 names, for neuroscience research.
• Ships from New Jersey, with warehousing across China, Europe & Japan for fast delivery.
• Competes on catalog breadth, next-day shipment & full analytical characterization with NMR, MS & HPLC data packs.
• Quality work covers assay above 98%, ISO 17025-aligned documentation & lot-specific certificates of analysis.

Cayman Chemical Company

• Distributes allopregnanolone reference material to academic and industrial neuroscience groups from Ann Arbor.
• Ships directly to research accounts and through third-party distributors in Europe & Asia.
• Competes on steroid catalog depth, technical support & documented characterization for GABA-A research.
• Quality documentation covers HPLC assay, chiral purity & lot-specific data packs.

Selleck Chemicals LLC

• Supplies reference-grade brexanolone in milligram-to-gram quantities for GABA-A and neurosteroid research.
• Ships from Houston, with regional warehousing in China, Europe & Japan.
• Competes on research-catalog reach, small-quantity availability & documented purity data.
• Quality work covers HPLC assay, structural confirmation & certificate of analysis for publication use.

Ligand Pharmaceuticals (Captisol excipient)

• Supplies betadex sulfobutyl ether sodium as Captisol, the cyclodextrin used to solubilize brexanolone in Zulresso.
• Ships Captisol to sterile-injectable formulators worldwide through direct supply and licensed makers.
• Its bearing on the finished product comes from the high cyclodextrin-to-drug ratio the complex needs.
• Regulatory record covers drug-master-file support for Captisol across many approved injectables.

Steroid API CDMOs (precursor and campaign supply)

• Chinese and Indian steroid houses run the pregnane and progesterone chemistry behind the brexanolone precursor.
• Precursor and campaign API supply is tied to contract steroid manufacturers in Hunan, Zhejiang & Hyderabad.
• These sites compete on steroid-synthesis scale, containment capability & flexible campaign slots.
• Regulatory work covers cGMP inspection, ICH Q7 & full CMC support for sponsor filings.